%0 Journal Article
%A Monforte, Victor
%A Ussetti, Piedad
%A Castejon, Raquel
%A Sintes, Helena
%A Luz Perez, Virginia
%A Laporta, Rosalia
%A Sole, Amparo
%A Manuel Cifrian, Jose
%A Marcos, Pedro J.
%A Redel, Javier
%A Los Arcos, Ibai
%A Berastegui, Cristina
%A Alonso, Rodrigo
%A Rosado, Silvia
%A Escriva, Juan
%A Iturbe, David
%A Pablo Ovalle, Juan
%A Manuel Vaquero, Jose
%A Lopez-Meseguer, Manuel
%A Mendoza, Alberto
%A Gomez-Olles, Susana
%T Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
%D 2021
%@ 0300-2896
%U https://hdl.handle.net/10668/25753
%X Introduction: Immune cell functional assay (ImmuKnow (R)) is a non-invasive method that measures the state of cellular immunity in immunosuppressed patients. We studied the prognostic value of the assay for predicting non-cytomegalovirus (CMV) infections in lung transplant recipients.Methods: A multicenter prospective observational study of 92 patients followed up from 6 to 12 months after transplantation was performed. Immune cell functional assay was carried out at 6, 8, 10, and 12 months.Results: Twenty-three patients (25%) developed 29 non-CMV infections between 6 and 12 months post-transplant. At 6 months, the immune response was moderate (ATP 225-525 ng/mL) in 14 (15.2%) patients and low (ATP = 525 ng/mL). Only 1 of 14 (7.1%) patients with a moderate response developed non-CMV infection in the following 6 months compared with 22 of 78 (28.2%) patients with low response, indicating sensitivity of 95.7%, specificity of 18.8%, positive predictive value (PPV) of 28.2%, and negative predictive value (NPV) of 92.9% (AUC 0.64; p = 0.043). Similar acute rejection rates were recorded in patients with mean ATP >= 225 vs. = 225 vs.
%K Immune cell assay
%K Immunosuppression
%K Infection
%K Lung transplant
%K Immunknow
%K Adenosine-triphosphate production
%K Recurrent hepatitis-c
%K Cylex immuknow assay
%K Working formulation
%K Allograft-rejection
%K Standardization
%K Experience
%K Risk
%~